|1.||Xu, Lan: 2 articles (07/2013 - 01/2013)|
|2.||Hong, Zhen: 2 articles (07/2013 - 01/2013)|
|3.||Hao, Yong: 1 article (07/2013)|
|4.||Yu, Peimin: 1 article (07/2013)|
|5.||Wu, Xunyi: 1 article (07/2013)|
|6.||Zhu, Guoxing: 1 article (07/2013)|
|7.||Wu, Xun-Yi: 1 article (01/2013)|
|8.||Wang, Jian-Hong: 1 article (01/2013)|
|9.||Fang, You-Xin: 1 article (01/2013)|
|10.||Zhu, Guo-Xing: 1 article (01/2013)|
09/01/1996 - "Tenidap is a novel, once-daily antirheumatic drug which has shown promising results against rheumatoid arthritis in extensive clinical trials. "
08/01/1990 - "Ten patients with rheumatoid arthritis (RA) were evaluated in a placebo-controlled, double-blind study examining the clinical efficacy of a novel nonsteroidal anti-inflammatory agent: Tenidap (CP-66,248). "
01/01/1996 - "The present double-blind, placebo-controlled study was conducted to compare the safety and efficacy of tenidap in patients with rheumatoid arthritis (RA). "
08/01/1997 - "Effect of tenidap on metalloproteinase gene expression in rheumatoid arthritis: a synovial biopsy study."
01/01/1995 - "Since numerous studies in patients with rheumatoid arthritis have shown that multiple dosing with tenidap is clinically efficacious, this suggests that the pharmacokinetic differences observed between the first and twenty-first day of multiple tenidap dosing do not influence the clinical response."
|2.||Hypertension (High Blood Pressure)
01/01/1995 - "5. The results of this study suggest that tenidap may be given to patients treated for mild to moderate essential hypertension controlled with thiazide therapy; however, the patient's blood pressure should be regularly monitored."
01/01/1995 - "2. Twenty-three male and female patients, aged 41-78 years, with mild to moderate, uncomplicated, essential hypertension controlled with thiazide diuretic therapy, received either a single daily dose of tenidap sodium 120 mg or matched placebo for 22 days in addition to their diuretic therapy. "
01/01/1995 - "The effect of tenidap on the anti-hypertensive efficacy of ACE inhibitors in patients treated for mild to moderate hypertension."
01/01/1995 - "The effect of tenidap on the anti-hypertensive efficacy of thiazide diuretics in patients treated for mild to moderate hypertension."
01/01/1995 - "1. A randomised, placebo controlled, double-blind, parallel group study was conducted to assess the effect of tenidap sodium, a novel cytokine modulating drug, on the stable hypotensive response to the angiotension converting enzyme (ACE) inhibitor enalapril in subjects with mild to moderate, uncomplicated, essential hypertension. "
02/01/1997 - "Group III (tenidap-treated) dogs had a slightly reduced incidence of osteophytes compared with the group II (12-week OA) dogs (71% versus 100%), and the size of the osteophytes was significantly diminished (mean +/- SEM 1.75 +/- 0.69 mm versus 4.38 +/- 0.64 mm). "
05/01/1997 - "Dogs treated with tenidap at both 1.5 and 0.5 mg/kg bid exhibited a reduction in the size of osteophytes (2.25 +/- 0.30 mm, 1.70 +/- 0.65 mm, respectively) compared to the 12 weeks OA group (3.55 +/- 0.94 mm). "
09/01/1995 - "Compared with the untreated or omeprazole-treated OA groups, the dogs treated with tenidap exhibited significant reduction in the incidence (P < or = 0.001) and size (P < or = 0.0001) of osteophytes. "
03/01/1998 - "The effect of tenidap treatment was evaluated on chemokine production in synovial membranes of rabbits with arthritis and in cultured monocytic and synovial cells (SC). "
12/01/1997 - "To determine whether tenidap regulates extracellular matrix metabolism in chronic arthritis. "
02/01/1996 - "Tenidap, a structurally novel drug for the treatment of arthritis: antiinflammatory and analgesic properties."
12/01/1997 - "Tenidap down-regulates the fibroproliferative changes typical of chronic arthritis, an effect that fits the profile of a disease-modifying agent for rheumatoid arthritis."
06/01/1995 - "After 24 weeks, improvement with tenidap was significantly greater than with diclofenac for all five primary efficacy parameters, two of the four secondary efficacy parameters and 11 of the 13 Arthritis Impact Measurement Scales assessments. "
|5.||Rheumatic Diseases (Rheumatism)
09/01/1996 - "Recent studies have indicated that, in addition to modulation of prostanoid and cytokine formation, tenidap has many other effects beneficial in rheumatic disease. "
04/01/1994 - "Cell cultures derived from patients with a variety of rheumatic diseases were cultured in different concentrations of Tenidap sodium, with or without IL-1, tumour necrosis factor alpha (TNF), IL-6, basic fibroblast growth factor (bFGF), or transforming growth factor beta (TGF beta). "
|1.||Interleukin-6 (Interleukin 6)
|2.||Diclofenac (SR 38)
|3.||Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)
|5.||Calcium Channel Blockers (Blockers, Calcium Channel)
|6.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|8.||Interleukin-1 (Interleukin 1)